JP2009533020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533020A5 JP2009533020A5 JP2009502208A JP2009502208A JP2009533020A5 JP 2009533020 A5 JP2009533020 A5 JP 2009533020A5 JP 2009502208 A JP2009502208 A JP 2009502208A JP 2009502208 A JP2009502208 A JP 2009502208A JP 2009533020 A5 JP2009533020 A5 JP 2009533020A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- structural element
- binding structural
- amino acid
- element according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 9
- 102000015685 human GM-CSF receptor-alpha subunit Human genes 0.000 claims 8
- 108010038879 human GM-CSF receptor-alpha subunit Proteins 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 5
- 102000046157 human CSF2 Human genes 0.000 claims 5
- 230000003472 neutralizing effect Effects 0.000 claims 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 238000001516 cell proliferation assay Methods 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004660 morphological change Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102220627452 Paired immunoglobulin-like type 2 receptor alpha_L95A_mutation Human genes 0.000 claims 1
- KLAONOISLHWJEE-QWRGUYRKSA-N Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KLAONOISLHWJEE-QWRGUYRKSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical group [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78656906P | 2006-03-27 | 2006-03-27 | |
| US60/786,569 | 2006-03-27 | ||
| PCT/GB2007/001108 WO2007110631A1 (en) | 2006-03-27 | 2007-03-27 | Binding member for gm-csf receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013002623A Division JP5665894B2 (ja) | 2006-03-27 | 2013-01-10 | Ｇｍ−ｃｓｆ受容体に対する結合構造要素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533020A JP2009533020A (ja) | 2009-09-17 |
| JP2009533020A5 true JP2009533020A5 (enExample) | 2010-05-13 |
| JP5335662B2 JP5335662B2 (ja) | 2013-11-06 |
Family
ID=38293698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502208A Active JP5335662B2 (ja) | 2006-03-27 | 2007-03-27 | Ｇｍ−ｃｓｆ受容体に対する結合構造要素 |
| JP2013002623A Active JP5665894B2 (ja) | 2006-03-27 | 2013-01-10 | Ｇｍ−ｃｓｆ受容体に対する結合構造要素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013002623A Active JP5665894B2 (ja) | 2006-03-27 | 2013-01-10 | Ｇｍ−ｃｓｆ受容体に対する結合構造要素 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8506960B2 (enExample) |
| EP (3) | EP2423229B1 (enExample) |
| JP (2) | JP5335662B2 (enExample) |
| KR (2) | KR101481844B1 (enExample) |
| CN (3) | CN101443360B (enExample) |
| BR (1) | BRPI0709259B1 (enExample) |
| CA (1) | CA2647449C (enExample) |
| DK (3) | DK1999152T3 (enExample) |
| ES (3) | ES2424468T3 (enExample) |
| MX (2) | MX2008012291A (enExample) |
| PL (3) | PL1999152T3 (enExample) |
| PT (3) | PT2423229E (enExample) |
| RU (2) | RU2495050C2 (enExample) |
| SI (3) | SI2423229T1 (enExample) |
| WO (1) | WO2007110631A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2527590B2 (ja) | 1988-02-17 | 1996-08-28 | 三洋電機株式会社 | 空冷式吸収冷凍機 |
| CN101443360B (zh) * | 2006-03-27 | 2013-11-27 | 医学免疫有限公司 | Gm-csf受体结合元件 |
| CN105435223A (zh) | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| CA2720614A1 (en) * | 2008-04-07 | 2009-10-15 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| AU2015224416B2 (en) * | 2008-12-22 | 2017-04-20 | The University Of Melbourne | Osteoarthritis treatment |
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| RU2712273C2 (ru) * | 2008-12-22 | 2020-01-28 | Де Юниверсити Оф Мельбурн | Лечение остеоартрита |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
| JP2012530047A (ja) * | 2009-05-05 | 2012-11-29 | モルフォシス・アー・ゲー | 多発性硬化症のための治療 |
| WO2011028697A2 (en) * | 2009-09-03 | 2011-03-10 | The Regents Of The University Of Colorado, A Body Corporate | Uses of cd 116 expression level |
| RU2014117510A (ru) * | 2011-10-10 | 2015-11-20 | Медиммьюн Лимитед | Лечение ревматоидного артрита |
| JP6426001B2 (ja) * | 2011-11-17 | 2018-11-21 | グリア エスピー ゼット．オー．オー． | 神経膠腫を治療するための組成物および方法 |
| EP2602264A1 (en) | 2011-12-05 | 2013-06-12 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | GDF-5 mutant for inducing cartilage formation |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2914289B1 (en) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
| EP2932264B1 (en) | 2012-12-14 | 2019-01-30 | BioNTech RNA Pharmaceuticals GmbH | Novel mhc-independent tumor-associated antigens |
| CN103193882B (zh) * | 2013-03-29 | 2014-11-05 | 浙江大学 | 胚胎干细胞特异性标志物GM-CSFRα及其应用 |
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| BR112016025126B1 (pt) | 2014-05-07 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma |
| AU2015263285A1 (en) * | 2014-05-19 | 2016-11-24 | Medimmune Limited | Treatment for rheumatoid arthritis |
| GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| MA45112A (fr) | 2016-05-24 | 2019-04-10 | Medimmune Ltd | Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde |
| EP3589318A1 (en) | 2017-03-01 | 2020-01-08 | MedImmune Limited | Formulations of monoclonal antibodies |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| KR20210090211A (ko) | 2018-11-09 | 2021-07-19 | 키닉사 파마슈티컬스, 리미티드 | 거대 세포 동맥염에 대한 치료 |
| WO2020096664A1 (en) | 2018-11-09 | 2020-05-14 | Kiniksa Pharmaceuticals, Ltd. | Treatment for giant cell arteritis |
| WO2020108423A1 (en) * | 2018-11-27 | 2020-06-04 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof |
| WO2020247521A1 (en) | 2019-06-03 | 2020-12-10 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
| WO2021141986A1 (en) * | 2020-01-07 | 2021-07-15 | St. Jude Children's Research Hospital, Inc. | Chimeric gmcsf-il18 receptor |
| WO2021188409A1 (en) | 2020-03-15 | 2021-09-23 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cytokine release syndrome with gm-csf antagonists |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| CN111690063A (zh) * | 2020-05-25 | 2020-09-22 | 北京大学 | 一种抗gm-csf纳米抗体及其制备方法和应用 |
| AU2021372454A1 (en) | 2020-10-26 | 2023-06-22 | Kiniksa Pharmaceuticals, Gmbh | Treatment of cancers with gm-csf antagonists |
| EP4263597A2 (en) | 2020-12-18 | 2023-10-25 | Kiniksa Pharmaceuticals, Ltd. | Protein compositions and methods for producing and using the same |
| CN116887856A (zh) * | 2022-01-20 | 2023-10-13 | 舒泰神（北京）生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5629283A (en) * | 1989-08-11 | 1997-05-13 | Amrad Corporation Limited | Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| EP0486572B1 (en) * | 1989-08-11 | 1998-01-07 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1994009149A1 (en) * | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994011404A1 (en) * | 1992-11-19 | 1994-05-26 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| PT1137941E (pt) | 1998-12-10 | 2009-10-15 | Brystol Myers Squibb Company | Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação |
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| EP1519958B1 (en) * | 2002-06-14 | 2014-10-15 | Immunomedics, Inc. | Humanized monoclonal antibody hpam4 |
| DK1572748T3 (da) * | 2002-12-17 | 2010-08-23 | Merck Patent Gmbh | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 |
| US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
| CN101443360B (zh) * | 2006-03-27 | 2013-11-27 | 医学免疫有限公司 | Gm-csf受体结合元件 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2007
- 2007-03-27 CN CN2007800154169A patent/CN101443360B/zh active Active
- 2007-03-27 DK DK07712963.3T patent/DK1999152T3/da active
- 2007-03-27 CA CA2647449A patent/CA2647449C/en active Active
- 2007-03-27 DK DK11167912.2T patent/DK2423229T3/da active
- 2007-03-27 KR KR20087026232A patent/KR101481844B1/ko active Active
- 2007-03-27 SI SI200731285T patent/SI2423229T1/sl unknown
- 2007-03-27 PL PL07712963T patent/PL1999152T3/pl unknown
- 2007-03-27 CN CN201310558011.7A patent/CN103641915B/zh active Active
- 2007-03-27 PT PT111679122T patent/PT2423229E/pt unknown
- 2007-03-27 EP EP11167912.2A patent/EP2423229B1/en active Active
- 2007-03-27 ES ES11167923T patent/ES2424468T3/es active Active
- 2007-03-27 PT PT77129633T patent/PT1999152E/pt unknown
- 2007-03-27 CN CN201310562197.3A patent/CN103641916A/zh active Pending
- 2007-03-27 EP EP07712963A patent/EP1999152B1/en active Active
- 2007-03-27 MX MX2008012291A patent/MX2008012291A/es active IP Right Grant
- 2007-03-27 JP JP2009502208A patent/JP5335662B2/ja active Active
- 2007-03-27 ES ES11167912T patent/ES2424467T3/es active Active
- 2007-03-27 BR BRPI0709259-8A patent/BRPI0709259B1/pt not_active IP Right Cessation
- 2007-03-27 PL PL11167923T patent/PL2423230T3/pl unknown
- 2007-03-27 EP EP11167923.9A patent/EP2423230B1/en active Active
- 2007-03-27 KR KR1020137029959A patent/KR101451546B1/ko active Active
- 2007-03-27 WO PCT/GB2007/001108 patent/WO2007110631A1/en not_active Ceased
- 2007-03-27 US US12/294,616 patent/US8506960B2/en active Active
- 2007-03-27 RU RU2008137763/10A patent/RU2495050C2/ru active
- 2007-03-27 PL PL11167912T patent/PL2423229T3/pl unknown
- 2007-03-27 MX MX2015007466A patent/MX348827B/es unknown
- 2007-03-27 ES ES07712963T patent/ES2395839T3/es active Active
- 2007-03-27 SI SI200731286T patent/SI2423230T1/sl unknown
- 2007-03-27 SI SI200731100T patent/SI1999152T1/sl unknown
- 2007-03-27 DK DK11167923.9T patent/DK2423230T3/da active
- 2007-03-27 PT PT111679239T patent/PT2423230E/pt unknown
- 2007-03-27 US US11/692,008 patent/US8263075B2/en active Active
-
2012
- 2012-12-26 RU RU2012157042A patent/RU2639546C2/ru active
-
2013
- 2013-01-10 JP JP2013002623A patent/JP5665894B2/ja active Active
- 2013-07-12 US US13/941,409 patent/US9085628B2/en active Active
-
2015
- 2015-06-29 US US14/753,792 patent/US20150376285A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,664 patent/US20190040145A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,850 patent/US20190309077A1/en not_active Abandoned
-
2020
- 2020-10-14 US US17/070,623 patent/US20210147559A1/en not_active Abandoned
-
2023
- 2023-10-31 US US18/499,051 patent/US20240124596A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533020A5 (enExample) | ||
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| JP2008527989A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2011508592A5 (enExample) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| RU2009124591A (ru) | Соединения | |
| JP2012525829A5 (enExample) | ||
| JP2012509881A5 (enExample) | ||
| RU2013123927A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173 | |
| JP2015502915A5 (enExample) | ||
| JP2014508511A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| US20130171146A1 (en) | Dual-specific il-1a/ il-1b antibodies | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| RU2011122720A (ru) | Члены связывания против il-1r1 | |
| BR112013017951B1 (pt) | Anticorpo de neutralização, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, uso de anticorpo e uso da composição farmacêutica | |
| RS57026B1 (sr) | Anti-n3pgiu amiloid beta peptid antitela i njihova upotreba | |
| JP2021101720A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| JP2012500020A5 (enExample) |